source
- FDA approves Egetis Therapeutics' Emcitate for rare X linked disease shortening life expectancy to 35 yearsEgetis Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its drug Emcitate. The therapy is intended for patients with a rare X linked genetic disorder that…
- SK pharmteco commits over $200 million to expand CDMO infrastructure, adding 100 jobs over five yearsSK pharmteco announced a plan to invest at least $200 million in building out its development and manufacturing infrastructure over the next five years. The funding is aimed at expanding the compa…